Performance of noninvasive fibrosis indices in chronic hepatitis B during pretreatment and post-treatment periods
Background: Pretreatment and post-treatment performances of noninvasive fibrosis indices were determined in patients with chronic hepatitis B. Method: This was a retrospective, single-center study. Results: The best area under the receiver operating characteristic curve values were detected for aspartate aminotransferase-to-alanine aminotransferase ratio (0.685) for ≥F2, Fibrosis Index (FI; 0.703) for ≥F3; FI (0.872) for ≥F4 and FI (0.864) for cirrhosis. After antiviral treatment, the best area under the receiver operating characteristic curve values were detected in aspartate aminotransferase-to-alanine aminotransferase ratio (0.615) for ≥F2; in FI based on four factors (FIB-4; 0.634) for ≥F3; in FIB-4 (0.678) for ≥F4 and in FIB-4 (0.814) for cirrhosis. Conclusion: FIB-4 and FI showed better performance in defining advanced fibrosis (≥F4) and cirrhosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Biomarkers in medicine - 17(2023), 19 vom: 01. Okt., Seite 799-809 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ozdemir, Yusuf E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AAR |
|---|
| Anmerkungen: |
Date Completed 18.01.2024 Date Revised 28.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/bmm-2023-0405 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366706098 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366706098 | ||
| 003 | DE-627 | ||
| 005 | 20240229234713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/bmm-2023-0405 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1311.xml |
| 035 | |a (DE-627)NLM366706098 | ||
| 035 | |a (NLM)38179991 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ozdemir, Yusuf E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Performance of noninvasive fibrosis indices in chronic hepatitis B during pretreatment and post-treatment periods |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2024 | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Pretreatment and post-treatment performances of noninvasive fibrosis indices were determined in patients with chronic hepatitis B. Method: This was a retrospective, single-center study. Results: The best area under the receiver operating characteristic curve values were detected for aspartate aminotransferase-to-alanine aminotransferase ratio (0.685) for ≥F2, Fibrosis Index (FI; 0.703) for ≥F3; FI (0.872) for ≥F4 and FI (0.864) for cirrhosis. After antiviral treatment, the best area under the receiver operating characteristic curve values were detected in aspartate aminotransferase-to-alanine aminotransferase ratio (0.615) for ≥F2; in FI based on four factors (FIB-4; 0.634) for ≥F3; in FIB-4 (0.678) for ≥F4 and in FIB-4 (0.814) for cirrhosis. Conclusion: FIB-4 and FI showed better performance in defining advanced fibrosis (≥F4) and cirrhosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AAR | |
| 650 | 4 | |a APRI | |
| 650 | 4 | |a FI | |
| 650 | 4 | |a FIB-4 | |
| 650 | 4 | |a chronic hepatitis B | |
| 650 | 7 | |a Alanine Transaminase |2 NLM | |
| 650 | 7 | |a EC 2.6.1.2 |2 NLM | |
| 650 | 7 | |a Aspartate Aminotransferases |2 NLM | |
| 650 | 7 | |a EC 2.6.1.1 |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Ozdemir, Meryem S |e verfasserin |4 aut | |
| 700 | 1 | |a Bayramlar, Osman F |e verfasserin |4 aut | |
| 700 | 1 | |a Kaya, Sibel Y |e verfasserin |4 aut | |
| 700 | 1 | |a Karaali, Rıdvan |e verfasserin |4 aut | |
| 700 | 1 | |a Balkan, Ilker I |e verfasserin |4 aut | |
| 700 | 1 | |a Mete, Bilgul |e verfasserin |4 aut | |
| 700 | 1 | |a Aygun, Gokhan |e verfasserin |4 aut | |
| 700 | 1 | |a Saltoglu, Nese |e verfasserin |4 aut | |
| 700 | 1 | |a Tabak, Fehmi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomarkers in medicine |d 2007 |g 17(2023), 19 vom: 01. Okt., Seite 799-809 |w (DE-627)NLM184946271 |x 1752-0371 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:19 |g day:01 |g month:10 |g pages:799-809 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/bmm-2023-0405 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 19 |b 01 |c 10 |h 799-809 | ||